{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T23:29:29Z","timestamp":1768260569440,"version":"3.49.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T00:00:00Z","timestamp":1749513600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T00:00:00Z","timestamp":1749513600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"NSFC","doi-asserted-by":"crossref","award":["82003872"],"award-info":[{"award-number":["82003872"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004735","name":"Natural Science Foundation of Hunan Province","doi-asserted-by":"publisher","award":["2022JJ50163, 2023JJ20034"],"award-info":[{"award-number":["2022JJ50163, 2023JJ20034"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Hunan Province Clinical Medical Technology Innovation Guidance Project","award":["2020SK51823, 2021SK51828, 2021SK51823"],"award-info":[{"award-number":["2020SK51823, 2021SK51828, 2021SK51823"]}]},{"name":"Hunan Provincial Clinical Medical Research Center for Drug Evaluation of major chronic diseases","award":["2023SK4040"],"award-info":[{"award-number":["2023SK4040"]}]},{"name":"The science and technology innovation Program of Hunan Province","award":["2023RC3173"],"award-info":[{"award-number":["2023RC3173"]}]},{"name":"Hunan Provincial Health High-Level Talent Scientific ResearchProject","award":["R2023074"],"award-info":[{"award-number":["R2023074"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Endocrinol Invest"],"DOI":"10.1007\/s40618-025-02625-1","type":"journal-article","created":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T02:00:11Z","timestamp":1749520811000},"page":"2111-2122","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Effects of sodium-glucose cotransporter 2 inhibitors on cardiomyopathy: a meta-analysis"],"prefix":"10.1007","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0594-9103","authenticated-orcid":false,"given":"Bo","family":"Xu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-4923-5142","authenticated-orcid":false,"given":"Tianqiao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3037-3997","authenticated-orcid":false,"given":"Jiecan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,6,10]]},"reference":[{"issue":"7","key":"2625_CR1","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1161\/CIRCRESAHA.117.309711","volume":"121","author":"WJ McKenna","year":"2017","unstructured":"McKenna WJ, Maron BJ, Thiene G (2017) Classification, epidemiology, and global burden of cardiomyopathies. Circ Res 121(7):722\u2013730","journal-title":"Circ Res"},{"issue":"10","key":"2625_CR2","first-page":"640","volume":"96","author":"J Brieler","year":"2017","unstructured":"Brieler J, Breeden MA, Tucker J (2017) Cardiomyopathy: an overview. Am Fam Physician 96(10):640\u2013646","journal-title":"Am Fam Physician"},{"issue":"14","key":"2625_CR3","doi-asserted-by":"publisher","first-page":"7722","DOI":"10.3390\/ijms22147722","volume":"22","author":"T Ciarambino","year":"2021","unstructured":"Ciarambino T, Menna G, Sansone G, Giordano M (2021) Cardiomyopathies: an overview. Int J Mol Sci 22(14):7722","journal-title":"Int J Mol Sci"},{"issue":"15","key":"2625_CR4","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1016\/j.jacc.2018.07.071","volume":"72","author":"JD Newman","year":"2018","unstructured":"Newman JD, Vani AK, Aleman JO, Weintraub HS, Berger JS, Schwartzbard AZ (2018) The changing landscape of diabetes therapy for cardiovascular risk reduction: JACC State-of-the-Art review. J Am Coll Cardiol 72(15):1856\u20131869","journal-title":"J Am Coll Cardiol"},{"key":"2625_CR5","unstructured":"Oktay AA, Paul TK, Koch CA, Lavie CJ et al (2023) Diabetes, Cardiomyopathy, and Heart Failure. In: Feingold KR, Anawalt B, Blackman MR, eds. Endotext. South Dartmouth (MA): MDText.com, Inc.; September 26"},{"key":"2625_CR6","doi-asserted-by":"publisher","unstructured":"Smati H, Qadeer YK, Rodriguez M et al (2024) Diabetic cardiomyopathy: what clinicians should know. Am J Med Published Online November 4. https:\/\/doi.org\/10.1016\/j.amjmed.2024.10.026","DOI":"10.1016\/j.amjmed.2024.10.026"},{"issue":"1","key":"2625_CR7","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1186\/s12933-024-02312-0","volume":"23","author":"HY Duan","year":"2024","unstructured":"Duan HY, Barajas-Martinez H, Antzelevitch C, Hu D (2024) The potential anti-arrhythmic effect of SGLT2 inhibitors. Cardiovasc Diabetol 23(1):252","journal-title":"Cardiovasc Diabetol"},{"issue":"10354","key":"2625_CR8","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/S0140-6736(22)01429-5","volume":"400","author":"M Vaduganathan","year":"2022","unstructured":"Vaduganathan M, Docherty KF, Claggett BL et al (2022) SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials. Lancet 400(10354):757\u2013767","journal-title":"Lancet"},{"issue":"18","key":"2625_CR9","first-page":"e895","volume":"145","author":"PA Heidenreich","year":"2022","unstructured":"Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, Deswal A, Drazner MH, Dunlay SM, Evers LR, Fang JC, Fedson SE, Fonarow GC, Hayek SS, Hernandez AF, Khazanie P, Kittleson MM, Lee CS, Link MS, Milano CA, Nnacheta LC, Sandhu AT, Stevenson LW, Vardeny O, Vest AR, Yancy CW (2022) 2022 AHA\/ACC\/HFSA guideline for the management of heart failure: A report of the American college of cardiology\/american heart association joint committee on clinical practice guidelines. Circulation 145(18):e895\u2013e1032","journal-title":"Circulation"},{"issue":"24","key":"2625_CR10","doi-asserted-by":"publisher","first-page":"2423","DOI":"10.1016\/j.jacc.2024.04.024","volume":"83","author":"SP Pinney","year":"2024","unstructured":"Pinney SP, Costanzo MR (2024) As good as it gets: SGLT2 inhibitors in cardiac amyloidosis. J Am Coll Cardiol 83(24):2423\u20132425","journal-title":"J Am Coll Cardiol"},{"issue":"10365","key":"2625_CR11","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1016\/S0140-6736(22)02074-8","volume":"400","author":"Nuffield Department of Population Health Renal Studies Group; SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists\u2019 Consortium","year":"2022","unstructured":"Nuffield Department of Population Health Renal Studies Group; SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists\u2019 Consortium (2022) Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials. Lancet 400(10365):1788\u20131801","journal-title":"Lancet"},{"issue":"7","key":"2625_CR12","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/S2213-8587(24)00102-5","volume":"12","author":"MS Usman","year":"2024","unstructured":"Usman MS, Bhatt DL, Hameed I et al (2024) Effect of SGLT2 inhibitors on heart failure outcomes and cardiovascular death across the cardiometabolic disease spectrum: a systematic review and meta-analysis. Lancet Diabetes Endocrinol 12(7):447\u2013461","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"20","key":"2625_CR13","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1161\/CIR.0000000000001186","volume":"148","author":"CE Ndumele","year":"2023","unstructured":"Ndumele CE, Neeland IJ, Tuttle KR et al (2023) A synopsis of the evidence for the science and clinical management of Cardiovascular-Kidney-Metabolic (CKM) syndrome: A scientific statement from the American heart association. Circulation 148(20):1636\u20131664","journal-title":"Circulation"},{"key":"2625_CR14","doi-asserted-by":"publisher","DOI":"10.1152\/physiol.00008.2024","author":"VG Yerra","year":"2024","unstructured":"Yerra VG, Connelly KA (2024) Extrarenal benefits of SGLT2 inhibitors in the treatment of cardiomyopathy. Physiology (Bethesda). Published online June. https:\/\/doi.org\/10.1152\/physiol.00008.2024","journal-title":"Published online June"},{"issue":"1","key":"2625_CR15","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s12933-023-01816-5","volume":"22","author":"K Huang","year":"2023","unstructured":"Huang K, Luo X, Liao B, Li G, Feng J (2023) Insights into SGLT2 inhibitor treatment of diabetic cardiomyopathy: focus on the mechanisms. Cardiovasc Diabetol 22(1):86","journal-title":"Cardiovasc Diabetol"},{"key":"2625_CR16","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71","journal-title":"BMJ"},{"key":"2625_CR17","doi-asserted-by":"crossref","unstructured":"Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (eds) (2019) Cochrane Handbook for Systematic Reviews of Interventions version 6.0 Cochrane, Available from www.training.cochrane.org\/handbook","DOI":"10.1002\/9781119536604"},{"issue":"16","key":"2625_CR18","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","volume":"385","author":"SD Anker","year":"2021","unstructured":"Anker SD, Butler J, Filippatos G et al (2021) Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med 385(16):1451\u20131461","journal-title":"N Engl J Med"},{"issue":"12","key":"2625_CR19","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","volume":"387","author":"SD Solomon","year":"2022","unstructured":"Solomon SD, McMurray JJV, Claggett B et al (2022) Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med 387(12):1089\u20131098","journal-title":"N Engl J Med"},{"issue":"7650","key":"2625_CR20","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","volume":"336","author":"GH Guyatt","year":"2008","unstructured":"Guyatt GH, Oxman AD, Vist GE et al (2008) GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 336(7650):924\u2013926","journal-title":"BMJ"},{"key":"2625_CR21","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ et al (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 366:l4898","journal-title":"BMJ"},{"issue":"1","key":"2625_CR22","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1002\/jrsm.1411","volume":"12","author":"LA McGuinness","year":"2021","unstructured":"McGuinness LA, Higgins JPT (2021) Risk-of-bias visualization (robvis): an R package and Shiny web app for visualizing risk-of-bias assessments. Res Synth Methods 12(1):55\u201361","journal-title":"Res Synth Methods"},{"issue":"7","key":"2625_CR23","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal B, Perkovic V, Mahaffey KW et al (2017) Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 377(7):644\u2013657","journal-title":"N Engl J Med"},{"issue":"4","key":"2625_CR24","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1038\/ki.2013.356","volume":"85","author":"DE Kohan","year":"2014","unstructured":"Kohan DE, Fioretto P, Tang W, List JF (2014) Long-term study of patients with type 2 diabetes and moderate renal impairment shows that Dapagliflozin reduces weight and blood pressure but does not improve glycemic control. Kidney Int 85(4):962\u2013971","journal-title":"Kidney Int"},{"issue":"2","key":"2625_CR25","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2204233","volume":"388","author":"EMPA-KIDNEY The","year":"2023","unstructured":"The EMPA-KIDNEY, Collaborative Group, Herrington WG, Staplin N et al (2023) Empagliflozin in patients with chronic kidney disease. N Engl J Med 388(2):117\u2013127","journal-title":"N Engl J Med"},{"issue":"21","key":"2625_CR26","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","volume":"381","author":"JJV McMurray","year":"2019","unstructured":"McMurray JJV, Solomon SD, Inzucchi SE et al (2019) Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 381(21):1995\u20132008","journal-title":"N Engl J Med"},{"issue":"15","key":"2625_CR27","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","volume":"383","author":"M Packer","year":"2020","unstructured":"Packer M, Anker SD, Butler J et al (2020) Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med 383(15):1413\u20131424","journal-title":"N Engl J Med"},{"issue":"20","key":"2625_CR28","doi-asserted-by":"publisher","first-page":"15078","DOI":"10.3390\/ijms242015078","volume":"24","author":"S Saha","year":"2023","unstructured":"Saha S, Fang X, Green CD, Das A (2023) mTORC1 and SGLT2 Inhibitors-A therapeutic perspective for diabetic cardiomyopathy. Int J Mol Sci 24(20):15078","journal-title":"Int J Mol Sci"},{"issue":"18","key":"2625_CR29","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1161\/CIRCULATIONAHA.122.061732","volume":"146","author":"M Packer","year":"2022","unstructured":"Packer M (2022) Critical reanalysis of the mechanisms underlying the cardiorenal benefits of SGLT2 inhibitors and reaffirmation of the nutrient deprivation signaling\/autophagy hypothesis. Circulation 146(18):1383\u20131405","journal-title":"Circulation"},{"issue":"1","key":"2625_CR30","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s12933-019-0816-2","volume":"18","author":"C Li","year":"2019","unstructured":"Li C, Zhang J, Xue M et al (2019) SGLT2 Inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart. Cardiovasc Diabetol 18(1):15","journal-title":"Cardiovasc Diabetol"},{"key":"2625_CR31","doi-asserted-by":"publisher","first-page":"102200","DOI":"10.1016\/j.tice.2023.102200","volume":"85","author":"SAG Eltobshy","year":"2023","unstructured":"Eltobshy SAG, Messiha R, Metias E et al (2023) Effect of SGLT2 inhibitor on cardiomyopathy in a rat model of T2DM: possible involvement of cardiac Aquaporins. Tissue Cell 85:102200","journal-title":"Tissue Cell"},{"key":"2625_CR32","doi-asserted-by":"publisher","first-page":"103010","DOI":"10.1016\/j.redox.2023.103010","volume":"69","author":"W Cai","year":"2024","unstructured":"Cai W, Chong K, Huang Y, Huang C, Yin L (2024) Empagliflozin improves mitochondrial dysfunction in diabetic cardiomyopathy by modulating ketone body metabolism and oxidative stress. Redox Biol 69:103010","journal-title":"Redox Biol"},{"issue":"5","key":"2625_CR33","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1093\/cvr\/cvad009","volume":"119","author":"R Madonna","year":"2023","unstructured":"Madonna R, Moscato S, Cufaro MC et al (2023) Empagliflozin inhibits excessive autophagy through the AMPK\/GSK3\u03b2 signalling pathway in diabetic cardiomyopathy. Cardiovasc Res 119(5):1175\u20131189","journal-title":"Cardiovasc Res"},{"issue":"1","key":"2625_CR34","doi-asserted-by":"publisher","first-page":"858","DOI":"10.3390\/ijms24010858","volume":"24","author":"W Zhang","year":"2023","unstructured":"Zhang W, Lu J, Wang Y et al (2023) Canagliflozin attenuates lipotoxicity in cardiomyocytes by inhibiting inflammation and ferroptosis through activating AMPK pathway. Int J Mol Sci 24(1):858","journal-title":"Int J Mol Sci"},{"key":"2625_CR35","doi-asserted-by":"publisher","first-page":"114310","DOI":"10.1016\/j.biopha.2023.114310","volume":"160","author":"D Croteau","year":"2023","unstructured":"Croteau D, Baka T, Young S et al (2023) SGLT2 inhibitor Ertugliflozin decreases elevated intracellular sodium, and improves energetics and contractile function in diabetic cardiomyopathy. Biomed Pharmacother 160:114310","journal-title":"Biomed Pharmacother"},{"issue":"16","key":"2625_CR36","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1056\/NEJMoa2314051","volume":"390","author":"J Butler","year":"2024","unstructured":"Butler J, Jones WS, Udell JA et al (2024) Empagliflozin after acute myocardial infarction. N Engl J Med 390(16):1455\u20131466","journal-title":"N Engl J Med"}],"container-title":["Journal of Endocrinological Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-025-02625-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40618-025-02625-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-025-02625-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T18:59:58Z","timestamp":1757185198000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40618-025-02625-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,10]]},"references-count":36,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,9]]}},"alternative-id":["2625"],"URL":"https:\/\/doi.org\/10.1007\/s40618-025-02625-1","relation":{},"ISSN":["1720-8386"],"issn-type":[{"value":"1720-8386","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,10]]},"assertion":[{"value":"23 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors declare that they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"<!--Emphasis Type='Bold' removed-->Competing interests"}},{"value":"The contents of this manuscript are original, and nothing in the manuscript has been published anywhere else.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Statement"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}]}}